Semaglutide vs. Tirzepatide: How They Compare

The easiest way to understand the difference is by looking at the receptors each medication targets.

Both influence systems involved in appetite, satiety, and metabolism. Tirzepatide simply approaches those systems through two incretin hormone pathways instead of one.

Your body naturally releases GLP-1 after eating. Among its effects, GLP-1 helps signal that food has arrived. Medications that activate GLP-1 receptors can help:

• Reduce appetite
• Increase feelings of fullness
• Slow gastric emptying
• Support glucose-dependent insulin secretion
• Reduce glucagon when appropriate

For someone who constantly feels hungry or has difficulty staying satisfied after eating, these effects can substantially change the weight-loss experience. Instead of fighting hunger every hour of the day, many patients describe simply feeling satisfied with less food.

GIP stands for glucose-dependent insulinotropic polypeptide. Like GLP-1, it's an incretin hormone involved in the body's response to food — and tirzepatide activates receptors for both GIP and GLP-1.

Researchers are still studying exactly how the combined activity produces all of tirzepatide's effects, but clinical trials have demonstrated substantial reductions in body weight. And now we have direct evidence comparing it with semaglutide.

For years, people compared separate semaglutide and tirzepatide trials. That wasn't ideal, because different trials involve different patients, designs, durations, and treatment protocols. Then came SURMOUNT-5.

This randomized phase 3b clinical trial directly compared tirzepatide and semaglutide in 751 adults with obesity who did not have type 2 diabetes. Participants received the maximum tolerated dose of either tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg) for 72 weeks.

In this head-to-head trial, tirzepatide produced significantly greater average weight loss.

Percentages can feel abstract. So imagine two hypothetical patients who both begin treatment at 220 pounds. Applying the average percentages from SURMOUNT-5:

• Semaglutide — 13.7%: approximately 30 pounds
• Tirzepatide — 20.2%: approximately 44 pounds

That's roughly a 14-pound difference when those trial averages are applied to a 220-pound starting weight.

But this is important: those are averages — not predictions. Some participants lost considerably more. Some lost less. And an individual patient's response can't be predicted simply by multiplying their weight by a clinical-trial percentage.

Not necessarily. If your only question is “Which produced greater average weight loss in a head-to-head obesity trial?” the answer is tirzepatide. But that's not the only question that matters when choosing medication.

Treatment decisions can also involve:

• Your medical history and previous GLP-1 experience
• Side-effect tolerance and treatment goals
• Cost, insurance coverage, and medication availability
• Contraindications and provider recommendations
• How your body actually responds

A medication doesn't need to produce the highest average number in a clinical trial to be a successful treatment for an individual patient.

This gets lost whenever tirzepatide and semaglutide are compared. Semaglutide didn't suddenly stop working because another medication produced greater average weight loss.

In the landmark STEP 1 trial, adults with overweight or obesity without diabetes receiving once-weekly semaglutide 2.4 mg alongside lifestyle intervention lost approximately 14.9% of their starting body weight over 68 weeks on average. That represented a major leap forward in obesity pharmacotherapy.

For someone starting at 220 pounds, 14.9% would represent roughly 33 pounds. Again, that's an illustration using a trial average — not a prediction of individual results. But it puts the magnitude into perspective. Semaglutide remains a highly effective treatment option for appropriate patients.

Because these medications affect the gastrointestinal system, their most common side effects tend to involve digestion. Both can cause:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal discomfort and other gastrointestinal symptoms

In SURMOUNT-5, gastrointestinal side effects were the most common adverse events with both medications. Most were mild to moderate and occurred primarily while doses were being increased. That's one reason GLP-1 treatment usually doesn't begin at the maximum dose.

Think about the difference between turning on a light switch and slowly turning up a dimmer. GLP-1 treatment is generally approached more like the dimmer.

Patients typically begin at a lower dose and gradually increase according to the prescribed titration schedule. This gives the body time to adjust. For many patients, the goal isn't “get to the highest dose as fast as possible.” It's “find a dose that produces a good response while remaining tolerable.” More medication isn't automatically better if the side effects make treatment impossible to continue.

There's no rule saying someone has to start with semaglutide before using tirzepatide. But semaglutide can still be an attractive first GLP-1 option for appropriate patients. It has:

• Extensive clinical experience
• Strong weight-loss evidence
• A well-established GLP-1 mechanism
• Multiple FDA-approved semaglutide products with substantial clinical data

For someone who doesn't necessarily need the greatest possible average weight reduction, semaglutide may provide plenty of weight-loss potential. You don't always need the most powerful option to get the result you're looking for.

Tirzepatide may be particularly interesting to someone whose priority is greater average weight-loss potential. The head-to-head evidence now makes that distinction much clearer.

Someone may also discuss tirzepatide with their provider if they previously used another GLP-1, didn't achieve their desired response, have a larger weight-loss goal, or want to discuss the dual GIP/GLP-1 approach — provided tirzepatide is medically appropriate for them. But again: more average weight loss doesn't automatically mean better treatment for every individual.

First, don't assume a plateau means the medication has completely stopped working. Weight loss isn't linear. It's normal for the scale to move quickly during certain periods and slowly during others.

A provider may review your current dose, how long you've been at that dose, appetite changes, nutrition, protein intake, physical activity, sleep, side effects, other medications, and how much weight you've already lost before deciding what happens next.

For some patients, continuing the current plan makes sense. For others, changing treatment may eventually be worth discussing. A plateau is a reason to review the plan — not automatically abandon it.

Potentially. Some patients do transition between GLP-1-based treatments under medical supervision. But the doses aren't equivalent — 5 mg of tirzepatide does not equal 5 mg of semaglutide. They're different medications with different dosing schedules.

You shouldn't try to calculate your own conversion based on numbers you see online. A healthcare provider should determine when to stop one medication, when to begin the other, what starting dose is appropriate, and how the new medication should be titrated based on the individual situation.

You've probably seen this phrase everywhere. Food noise isn't a formal medical diagnosis — it's the way many patients describe persistent thoughts about food: “What am I eating next?” “I'm still hungry.” “Should I snack?” “I can't stop thinking about food.”

Because semaglutide and tirzepatide influence appetite and satiety pathways, some patients report that these thoughts become less intense during treatment. That can be one of the most meaningful changes for someone who has spent years feeling like weight loss requires constantly fighting their appetite.

This matters with both medications. Whenever someone loses a substantial amount of body weight, some of that weight can come from lean mass — not only body fat.

That's why a good weight-management program shouldn't focus exclusively on making the number on the scale smaller. It should also emphasize adequate protein, resistance training when appropriate, regular physical activity, appropriate nutrition, and long-term body composition. The goal isn't simply to become lighter. It's to improve health while preserving as much strength and function as possible.

Be careful with this question. Neither medication should be treated like a crash diet. Both are typically titrated gradually. Some patients notice appetite changes relatively early; meaningful weight loss generally develops over months, not days.

And because tirzepatide produced greater average weight loss over 72 weeks in SURMOUNT-5, that doesn't mean every tirzepatide patient will lose weight faster than every semaglutide patient. Your individual response matters more than somebody else's week-by-week progress.

Semaglutide may make sense if you're looking for a proven GLP-1 approach, significant weight-loss potential, extensive clinical evidence, a treatment that may already be enough to reach your goals, or a medication your provider believes better fits your situation.

Tirzepatide may make sense if you're particularly interested in greater average weight-loss potential, dual GIP + GLP-1 activity, larger weight-loss goals, or an alternative after previous GLP-1 treatment — when medically appropriate.

Don't choose based exclusively on “which medication loses the most weight?” Start with “how much weight do I actually need to lose?” Then consider your medical history, previous GLP-1 experience, side-effect sensitivity, what you can realistically afford long term, what your provider recommends, and which treatment you can actually stay consistent with.

Because the best medication isn't necessarily the one with the biggest number attached to it. It's the treatment that produces meaningful results and that you can safely and realistically continue.

Semaglutide and tirzepatide are both powerful tools for medical weight management. But they're not identical.

Semaglutide targets the GLP-1 receptor and has extensive clinical evidence supporting significant weight reduction in appropriate patients. Tirzepatide targets both GIP and GLP-1 receptors and has demonstrated greater average weight reduction in a direct head-to-head obesity trial — 20.2% vs. 13.7% average weight reduction at 72 weeks in SURMOUNT-5.

That's a meaningful difference. But it doesn't make semaglutide the “bad” option or tirzepatide automatically the “right” option. The goal isn't to choose the strongest medication. It's to choose the right treatment for the person taking it.